Results of a phase I study of Bendamustine in Combination with Ofatumumab, Carboplatin and Etoposide (BOCE) for Refractory of Relapsed Aggressive B-cell Non Hodgkin's Lymphomas (NHL)

Authors

Sameh Gaballa, MD, Thomas Jefferson University HospitalFollow
Neil D. Palmisiano, MD, Thomas Jefferson UniversityFollow
Aakanksha Asija, MD, Thomas Jefferson UniversityFollow
Andrew Chapman, DO, Thomas Jefferson UniversityFollow
Jennifer K. Cloud, BS, Thomas Jefferson UniversityFollow
Joanne Filicko-O'Hara, MD, Thomas Jefferson UniversityFollow
Lewis Rose, MD, Thomas Jefferson UniversityFollow
Michael Ramirez, MD, Thomas Jefferson UniversityFollow
Onder Alpdogan, MD, Thomas Jefferson UniversityFollow
Neal Flomenberg, MD, Thomas Jefferson UniversityFollow
Barbara Pro, MD, Thomas Jefferson UniversityFollow
Elena Gitelson, MD, PhD, Thomas Jefferson UniversityFollow
Mark Weiss, MD, Thomas Jefferson UniversityFollow

Document Type

Poster

Publication Date

6-2-2014

Comments

Presented at ASCO (American Society of Clinical Oncology) June 2 2014

Abstract

Introduction:

• There are a number of regimens used to treat relapsed/refractory aggressive lymphomas and little consensus exists on the best salvage treatment.
• No regimen has shown clear superiority but uniformly there was an inferior outcome among patients who had relapsed after a prior rituximab containing regimen.
• Ofatumumab is a fully human IgG1k monoclonal anti-CD20 antibody. It recognizes a distinct epitope on the human CD20 molecule. In vitro studies with ofatumumab have shown more complement dependent cytotoxicity than rituximab.
• Bendamustine has single agent activity in relapsed aggressive lymphomas and has a favorable safety profile.

Objectives:

• We conducted a phase I trial using a novel RICE-like salvage combination regimen in which ofatumumab is substituted for rituximab and bendamustine replaces ifosfamide in combination with carboplatin and etoposide (BOCE) to assess the safety and toxicity profile of this combination.
• The objective from the phase I part of this trial was to assess safety and tolerability of this combination.

Recommended Citation

Gaballa, MD, Sameh; Palmisiano, MD, Neil D.; Asija, MD, Aakanksha; Chapman, DO, Andrew; Cloud, BS, Jennifer K.; Filicko-O'Hara, MD, Joanne; Rose, MD, Lewis; Ramirez, MD, Michael; Alpdogan, MD, Onder; Flomenberg, MD, Neal; Pro, MD, Barbara; Gitelson, MD, PhD, Elena; and Weiss, MD, Mark, "Results of a phase I study of Bendamustine in Combination with Ofatumumab, Carboplatin and Etoposide (BOCE) for Refractory of Relapsed Aggressive B-cell Non Hodgkin's Lymphomas (NHL)" (2014). Department of Medical Oncology Faculty Papers. Paper 32.
https://jdc.jefferson.edu/medoncfp/32